Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Pfizer
UMC Utrecht
Neonc Technologies, Inc.
Adela, Inc
Jonsson Comprehensive Cancer Center
CNAO National Center of Oncological Hadrontherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Apollomics Inc.
Columbia University
Algemeen Ziekenhuis Maria Middelares
Vanderbilt-Ingram Cancer Center
University of Sydney
Shanghai Yunying Medical Technology